Clinical trials: Human Immunodeficiency Virus Type 1
HIV-1-infection, Contraception
Darunavir and Rilpivirine Interactions With Levonorgestrel Implant
This study will evaluate the pharmacokinetic properties of Rilpivirine and Darunavir when used in combination with Levonorgestrel
- Trial name
- DRIVE-2 (NCT03589027)
- Testing
- Levonorgestrel two rod sub-dermal implant, Rilpivirine, Darunavir+Ritonavir
- Where
- Uganda
- Volunteers
- 60 people
- Sponsor
- Makerere University
HIV, HBV
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
This study will assess the efficacy, safety, and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in human immunodeficiency virus (HIV)/hepatitis B virus (HBV)…
- Trial name
- NCT02071082
- Testing
- E/C/F/TAF
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 79 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults
The purpose of this study is to evaluate the safety of and immune response to two HIV vaccine formulations, rMVA-HIV and rFPV-HIV, alone and in combination, in HIV uninfected adults.
- Trial name
- NCT00083603
- Testing
- rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT), rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT), Empty TBC-FPV
- Where
- 6 sites in United States, Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection
A phase Ib partially blinded pilot study to evaluate the safety and immunological effects of PENNVAX-B with or without co-administration of constructs containing DNA encoding for the expression of either IL-12 or IL-15.
- Trial name
- NCT00775424
- Testing
- PENNVAX-B, GENEVAX IL-12-4532, IL-15 adjuvant
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Pennsylvania
Hepatitis C
A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
The purpose of the study is to determine if combination therapy with daclatasvir (DCV) and sofosbuvir (SOF) for 8 weeks is safe and effective in patients who have never been treated previously without liver cirrhosis who are…
- Trial name
- NCT02556086
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 17 sites in Canada, France
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid
This protocol is intended to test the feasibility of using the HIV 1/2 STAT-PAK and the DPP HIV 1/2 test (with and without the DPP Handheld Reader) to detect HIV antibodies in oral fluids.
- Trial name
- HIVOF (NCT00636220)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Chembio Diagnostic Systems, Inc.
HIV
TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
The purpose of this study is research with the goal of evaluating the effect of TMC125 (a non-nucleoside reverse transcriptase inhibitor) on slowing down the growth of the HIV virus.
- Trial name
- NCT00254046
- Testing
- TMC125
- Where
- 55 sites in United States, Argentina and 8 more
- Volunteers
- 616 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1-infection
Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection
The efficacy and safety of Biktarvy in Treatment-Naïve Late Presenters with HIV-1 Infection
- Trial name
- NCT04296695
- Testing
- B/F/TAF, TDF/3TC/EFV
- Where
- 5 sites in China
- Volunteers
- 202 people
- Sponsor
- Peking Union Medical College Hospital
HIV-1-infection
Impact of V106I on Resistance to Doravirine
Objective. To study the impact of V106I mutation in the reverse transcriptase of HIV-1 on the activity of Doravirine. Clinical hypotheses.
- Trial name
- V106IFC (NCT04894357)
- Testing
- Phenotypic resistance measure
- Volunteers
- 50 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
HIV Infections
Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection
This study will compare the immune response and side effects of an experimental HIV vaccine given by two different methods of administration by needle injection or by use of a needle-free device called the Biojector 2000…
- Trial name
- NCT00709605
- Testing
- VRC-HIVADV014-00-VP
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Adherence to Dolutegravir and Outcome
The main assumption is that the dolutegravir can get virologic suppression to suboptimal adherence levels (between 80 and 95%, and after treatment interruptions) where other molecules are not capable, due to their…
- Trial name
- DOLUTECAPS (NCT02878642)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Caen
Infection, Human Immunodeficiency Virus I, HIV Infection
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily.
- Trial name
- NCT00082394
- Testing
- Trizivir, atazanavir, Combivir
- Where
- 45 sites in United States, Mexico
- Sponsor
- GlaxoSmithKline
HIV Infections
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions.
- Trial name
- NCT00000872
- Testing
- Abacavir sulfate, Nelfinavir mesylate, Nevirapine
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas
The goal of this implementation science study is to learn about the experience of receiving and providing cabotegravir + rilpivirine long-acting (CAB+RPV LA) injections as treatment for human immunodeficiency virus (HIV) for…
- Trial name
- IM-CAPABLE (NCT06451341)
- Testing
- Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), Feasibility of Intervention Measure (FIM)
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Nebraska
Hiv
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good…
- Trial name
- NCT05001373
- Testing
- Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine
- Where
- 4 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infections
A Pilot Study of LTB4 in HIV-1 Infected Adults
This is a pilot study to assess the safety and antiretroviral activity of a naturally occuring substance known as Leukotriene B4(LTB4).
- Trial name
- NCT00251537
- Testing
- LTB4
- Where
- 7 sites in Canada
- Volunteers
- 40 people
- Sponsor
- LTB4 Sweden AB
HIV-1
Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions
In this study, the investigators evaluated a therapeutic HIV-1 DNA vaccine administered with a novel topical application method to 12 chronically HIV-infected cART treated patients.
- Trial name
- Vac09 (NCT01140139)
- Testing
- HIV DNA Vaccine
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Swedish Institute for Infectious Disease Control
HIV Infections
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
Elvucitabine, a novel nucleoside analog, is being studied as a treatment for participants with human immunodeficiency virus (HIV)-1.
- Trial name
- NCT00350272
- Testing
- Elvucitabine, Lamivudine, Tenofovir
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 76 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
The purpose of this study is to compare the anti-HIV efficacy, safety and effect of serum lipids of two boosted protease inhibitor-based HAART regimens (ARV/RTV v.
- Trial name
- NCT00135395
- Testing
- Atazanavir+ritonavir, Lopinavir+ritonavir
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Safety of Acidform Lubricant in HIV-Uninfected Women
Topical microbicides, substances that kill microbes, are being studied to prevent sexual transmission of HIV and other disease pathogens.
- Trial name
- NCT00850837
- Testing
- Acidform Lubricant, HEC gel
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.